Syncor posts healthy 1998 numbers

Article

Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997’s $1.7 million. Net sales for the quarter increased 25% to $119 million, up

Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997’s $1.7 million. Net sales for the quarter increased 25% to $119 million, up from $94.8 million. The Woodland Hills, CA, company enjoyed net sales for the year of $449 million, up 18% from $380.6 million in 1997, and net income of $13.9 million, compared with $11.1 million the year before.

Syncor attributed its healthy results to its first price increase in six years, as well as its effort to control costs, which improved its gross margins. The company increased its operating income for its radiopharmacy business in 1998 to $21.4 million, up 64% from $13 million in 1997. In addition, Syncor’s imaging center subsidiary, Comprehensive Medical Imaging, contributed $37.5 million in sales to the company in fiscal 1998.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.